The Key Laboratory of Small Molecule Immuno-Oncology Drug Discovery of Chinese Academy of Medical Sciences focuses on the discovery and development of innovative drugs with new mechanisms/targets in the field of immuno-oncology.
The research interests include: 1. establishment of pharmacological evaluation platform for immuno-oncology drugs, such as establishing molecular, cellular and animal-level assays/models based on the molecular characteristics of immuno-oncology drugs; improving key technologies as reconstruction of the immune system in nude mice, and efficiently evaluating antitumor drug efficacies acting through immune mechanism. 2. discovery and development of novel small molecule immuno-oncology drugs targeting PD-L1, LAG3, STAT3, CXCR2, IDO and PI3Kδ.
Based on the established R&D platform, the key laboratory aims to achieve the unmet clinical requirements by accelerating breakthrough advances in immuno-oncology research. The key laboratory has made significant advance in discovery and development of innovative drugs as well as transfer of scientific and technological achievement. Among them, the PD-L1 small molecule inhibitor Immdiphen obtained IND approval from the NMPA in August, 2019, and is currently undergoing clinical trials; the PI3K inhibitor Anquilisib has completed preclinical studies and filed pre-IND submission. Both Immdiphen and Anquilisib have been licensed out to leading pharmaceutical companies and achieved the commercialization of scientific achievements.
